

SCIENCE'S COMPASS

Paul Lucassen

Leiden University, 2300 RA Leiden, Netherlands

Hans Lassmann

Neurological Institute, University of Vienna, Vienna, Austria

Mark A. Smith

Institute of Pathology, Case Western University

References

1. G. Perry, A. Nunomura, M. A. Smith, *Nature Med.* **4**, 897 (1998).

Genetics of Alcoholism

We disagree with the interpretations of Ernest P. Noble (Letters, *Science's Compass*, 28 Aug., p. 1287), of the results of our recent study (1). The Collaborative Study on the Genetics of Alcoholism (COGA) tested the hypothesis that the D2 dopamine receptor gene (*DRD2*) TaqI-A polymorphism was associated with alcoholism. We used the transmission disequilibrium test (TDT), a family-based method that compares alleles transmitted by heterozygous parents to their affected offspring with the alleles that could have been (but were not) transmitted (2). Because the TDT uses control alleles and does not use control individuals, Noble's discussion of the supposed problem with controls in the COGA study is not relevant to our results.

We tested individuals defined as alcohol-dependent by any of three criteria: those of the *Diagnostic and Statistical Manual of Mental Disorders* (DSM), 4th edition (3); the *International Classification of Disease*, 10th edition (4); and "COGA criteria" [alcohol dependence by DSM-III (revised) criteria (5), plus definite alcoholism by Feighner criteria (6)]. In no case was there any evidence that the TaqI-A1 allele was associated with alcoholism. Tests of a more informative simple tandem repeat polymorphism (STRP) marker in intron 2 were also negative. In light of the controversy surrounding this hypothesis, we tested the hypothesis in multiple ways; none of these tests provided evidence for either linkage or association of the *DRD2* gene with alcohol dependence.

To avoid missing any potential association, we also examined unaffected individuals in these families and again found no evidence of association (1). Noble appears to misinterpret our definition of unaffected in this part of our study. Unaffected individuals had 0, up to 4, or up to 8 of 37 symptoms collected in the interview instrument, the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA) (7). These were symptoms, not criterion items for diagnosis. If they had been criterion items, no one with more than three could have been diagnosed as unaffected. As we stated in our paper, none met criteria for diagnosis of either

alcohol abuse or dependence. The data for unaffected individuals did not show evidence for association of the *DRD2* gene with alcoholism.

Sib-pair analyses also provided no evidence of linkage (1, 8). Noble quotes two studies using sib-pairs (9, 10). As discussed in our paper (1), the first provided no evidence for linkage with the alcohol dependence syndrome; all of the putative evidence for linkage with heavy drinking came from one large sibship analyzed with no correction for non-independence (9). Neither the remaining families nor the replication sample gave any evidence for linkage (9). The other study (10) notes a nearly significant ($p = 0.06$) result by one technique that could not be replicated by more powerful analyses, including TDT, and therefore represents a negative report, in line with ours. An earlier study by the same group also found no linkage, although reporting a population association (11).

In summary, our study used a powerful method of analysis that avoids the major pitfall of previous association studies, the proper matching of controls. It yielded no evidence that the *DRD2* TaqI-A1 allele or an STRP in the same gene is associated with alcoholism.


Howard J. Edenberg,

Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202-5122, USA. E-mail: edenbergh@iupui.edu; **Tatiana Foroud,** Indiana University School of Medicine. E-mail: foroud@medgen.iupui.edu; **Alison Goate, John Rice, Theodore Reich, C. Robert Cloninger,** Washington University School of Medicine, St. Louis, MO 63110, USA; **John I. Nurnberger Jr., T.-K. Li, P. M. Conneally, Jay A. Tischfield,** Indiana University School of Medicine; **Raymond Crowe,** University of Iowa College of Medicine, Iowa City, IA 52242-1000, USA; **Victor Hesselbrock,** University of Connecticut Health Center, Farmington, CT 06030-2103, USA; **Marc Schuckit,** University of California, San Diego, San Diego, CA 92161-2002, USA; **Bernice Porjesz** and **Henri Begleiter,** State University of New York Health Sciences Center, Brooklyn, NY 11203-2098, USA.

References

1. H. J. Edenberg et al., *Alcohol. Clin. Exp. Res.* **22**, 505 (1998).
2. R. S. Spielman and W. J. Ewens, *Am. J. Hum. Genet.* **59**, 983 (1996).
3. *Diagnostic and Statistical Manual of Mental Disorders* (American Psychiatric Association Press, Washington, DC, ed. 4, 1994).
4. *International Classification of Disease* (World Health Organization, Geneva, ed. 10, 1993).
5. *Diagnostic and Statistical Manual of Mental Disorders* (American Psychiatric Association Press, Washington, DC, ed. 3, rev., 1987).
6. E. P. Noble et al., *Alcohol. Alcohol.* **29**, 729 (1994).
7. K. K. Bucholz et al., *J. Stud. Alcohol.* **55**, 149 (1994).
8. T. Reich et al., *Am. J. Med. Genet. (Neuropsychol. Genet.)* **81**, 207 (1998).
9. C. C. Cook et al., *Br. J. Psychiatr.* **169**, 243 (1996).
10. D. Goldman, M. Urbanek, D. Guenther, R. Robin, J. C. Long, *Alcohol* **16**, 47 (1998).
11. K. Neiswanger, S. Y. Hill, B. B. Kaplan, *Am. J. Med. Genet.* **60**, 267 (1995).

AdvanTaq Plus™ & TaqStart™ Antibody



AdvanTaq Plus offers higher sensitivity. Amplification of a 158-bp fragment of the human Δ lactoferrin gene. Human genomic DNA and mouse genomic DNA were combined in a decreasing ratio.

AdvanTaq Plus combines the new AdvanTaq DNA Polymerase for sensitive, robust amplification with TaqStart Antibody for increased specificity and yield. Use AdvanTaq Plus instead of Taq for reliable, consistent performance with little or no optimization or additional steps in any routine PCR application.

TaqStart Antibody is a neutralizing monoclonal antibody to Taq that prevents the formation of background such as primer dimers. TaqStart can be purchased separately to add a hot start to any PCR reaction. Just dilute TaqStart and mix with your DNA polymerase.

Call and order today!

CLONTECH

NOW YOU CAN.

CLONTECH Laboratories, Inc.

Tel: 800-662-2566 (CLON) • 650-424-8222

Fax: 800-424-1350 • 650-424-1088 • Internet: www.clontech.com
E-mail: products@clontech.com • orders@clontech.com

SUBSIDIARIES

CLONTECH GmbH • Tel: 06221 34170 • Fax: 06221 303511
CLONTECH Japan Ltd. • Tel: 03 5643 3271 • Fax: 03 5643 3252
CLONTECH UK Ltd. • Tel: 01256 476500 • Fax: 01256 476499

(9/3/98)

© 1998, CLONTECH Laboratories, Inc.

(AF8X979)

Circle No. 46 on Readers' Service Card